ClinicalTrials.gg
CompletedNCT01580020Updated May 17, 2016Results posted

Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO

A Phase 4 interventional study of RFB002 and Dexamethasone in Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 37 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
175
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.

Enrollment
12th of 47
175 · median 56
Started
2012
with 4 others
Phase 4
13 of 47
none open now
Registered
25th of 47
by date
Lead sponsor
9 of 47
Novartis Pharmaceuticals

Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 12th largest by enrollment, is one of 5 that started in 2012, is one of 13 in phase 4, and was the 25th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 47 studies testing ranibizumab in Retinal Vein Occlusion as a file.
02

Study summary

The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the initial 6-month treatment in the respective core studies CRFB002EDE17 (NCT01396057) and CRFB002EDE18 (NCT01396083).

03

Conditions studied

  • Retinal Vein Occlusion

Keywords

  • Macular Degeneration
  • Macular Edema
  • Retinal Vein Occlusion
  • Choroidal Neovascularization
  • Signs and Symptoms
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases
  • Venous Thrombosis Sensation Disorders
  • Dexamethasone acetate
  • Dexamethasone
  • Dexamethasone 21-phosphate
  • BB 1101
  • Anti-Inflammatory Agents
  • Therapeutic Uses
  • Vision, Low
  • Signs
  • Vision Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have completed the core study assessments at month 6 of study CRFB002EDE17 or CRFB002EDE18, respectively

Exclusion criteria

Exclusion Criteria:

  • Patients who experienced an uncontrollable rise in IOP during the core study CRFB002EDE17 respectively CRFB002EDE18, i.e. IOP could not be decreased to a stable level of \< 25mmHg.
  • Use of other drugs
  • Current use or likely need of systemic medications known to be toxic to the lens, retina or optic nerve
  • History of to Ranibizumab or Ozurdex or any component of the ranibizumab respectively Ozurdey formulation
  • Any type of advanced, severe or unstable disease or its treatment, that could interfere with evaluations or put the patient at special risk
  • Women
  • who were pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/mL)
  • who were menstruating and capable of becoming pregnant* and not practicing a medically approved method of (Pearl Index \<1**)*** during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche was required with sufficient lead time before randomization

    • definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy

      • examples of particularly reliable methods with Pearl Index (PI) \<1, according to guidelines of "Deutsche Gesellschaft für Gynäkologie und Geburtshilfe":

        • Combination pill with estrogen and gestagen (no mini-pill, PI=0.1-0.9)
        • Vaginal ring (NuvaRing®, PI=0.65 uncorr.; 0.4 corr.)
        • Contraceptive patch (EVRA®, PI= 0.72 uncorr.; 0.9 corr.)
        • Estrogen-free ovulation inhibitors (Cerazette®, PI=0.14)
        • Progestin-containing contraceptives (Implanon®, PI=0-0.08)
        • Injectable 3-month depot progestins (PI=0.3-1.4; 0.88 corr.)
        • Intra-uterine progestin device (Mirena®, PI=0.16)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Ranibizumab (Arm A)

    The PRN injection scheme applied in the core study will also be followed during this extension study: Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month

    Biological: RFB002

  • Sham comparator
    Dexamethasone (Arm B)

    A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.

    Drug: Dexamethasone

Interventions

  • BiologicalRFB002

    0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.

  • DrugDexamethasone

    Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    The number of participants who experienced Adverse events, serious AE and death

    Time frame: 6 months

Secondary outcomes

  1. Raw Mean Best Corrected Visual Acuity (BCVA) by Treatment Group

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement

    Time frame: Baseline, 6 months and 12 months

  2. Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters at Month 12 Compared to Baseline

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who were gaining/losing ≥15, 10 or 5 more letters of visual acuity at month 12 as compared with baseline

    Time frame: 12 month

  3. Change in Central Subfield Thickness (CSRT) From Baseline to Month 12

    High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.

    Time frame: Baseline , Month 12

  4. Change of Foveal Center Point Thickness (FCPT) From Baseline to Month 12

    FCPT (foveal center point thickness) was assessed by central reading center to ensure error- corrected measurements of retinal thickness and volumes,

    Time frame: Baseline, Month 12

  5. Change in Mean Visual Function Questionnaire (VFQ-25)

    The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.

    Time frame: Baseline, 12 months

  6. Change in SF-36 Summary Scores

    The SF-36 measures the impact of disease on overall quality of life and consists of eight subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health. A positive change from Baseline score indicates improvement in quality of life.

    Time frame: Baseline, month 12

  7. Change in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores

    The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).

    Time frame: Baseline, month 12

  8. Time to the First Retreatment of Both Treatment Arms

    Time to the first retreatment

    Time frame: 6 months

07

Results

Posted May 17, 2016

Participant flow

A total of 140 patients with (BRVO) completed the core study CRFB002EDE17, and 127 patients with (CRVO) completed the core study CRFB002EDE18. 92 patients with BRVO and 83 patients with CRVO were enrolled into the extension study. A total of 175 patients (113 in the ranibizumab group and 62 in the dexamethasone group) were enrolled

Participant flow — Overall Study
MilestoneRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Started52406122
Completed51335720
Not completed1742
Withdrew: Lack of efficacy0501
Withdrew: Withdrawal by subject0110
Withdrew: Adverse event1111
Withdrew: Administrative problems0010
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability

The number of participants who experienced Adverse events, serious AE and death

Time frame:
6 months
Reported as:
Number · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Adverse event35284516
Serious adverse event2361
Death0000
SecondaryRaw Mean Best Corrected Visual Acuity (BCVA) by Treatment Group

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement

Time frame:
Baseline, 6 months and 12 months
Reported as:
Mean · Letters read correctly
Raw Mean Best Corrected Visual Acuity (BCVA) by Treatment Group
Letters read correctlyRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Baseline56.8 ± 10.058.3 ± 10.853.8 ± 15.753.2 ± 16.1
Month 677.9 ± 10.669.2 ± 11.972.6 ± 13.564.1 ± 24.0
Month 1279.0 ± 10.170.6 ± 13.972.6 ± 15.866.6 ± 22.3
SecondaryPercentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters at Month 12 Compared to Baseline

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who were gaining/losing ≥15, 10 or 5 more letters of visual acuity at month 12 as compared with baseline

Time frame:
12 month
Reported as:
Number · Percentage of participants
Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters at Month 12 Compared to Baseline
Percentage of participantsRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Gain≥15 letters80.850.058.345.5
Gain ≥10 letters88.565.075.068.2
Gain ≥5 letters100.080.086.777.3
Loss of ≥15 letters0.07.50.04.5
Loss of ≥10 letters0.010.00.04.5
Loss of ≥5 letters0.010.03.34.5
SecondaryChange in Central Subfield Thickness (CSRT) From Baseline to Month 12

High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.

Time frame:
Baseline , Month 12
Reported as:
Mean · um
Change in Central Subfield Thickness (CSRT) From Baseline to Month 12
umRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Change in Central Subfield Thickness (CSRT) From Baseline to Month 12-288.1 ± 180.6-211.5 ± 199.3-374.6 ± 239.8-360.3 ± 260.2
SecondaryChange of Foveal Center Point Thickness (FCPT) From Baseline to Month 12

FCPT (foveal center point thickness) was assessed by central reading center to ensure error- corrected measurements of retinal thickness and volumes,

Time frame:
Baseline, Month 12
Reported as:
Mean · um
Change of Foveal Center Point Thickness (FCPT) From Baseline to Month 12
umRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Change of Foveal Center Point Thickness (FCPT) From Baseline to Month 12-341.8 ± 226.2-252.6 ± 197.9-439.4 ± 279.8-432.3 ± 245.8
SecondaryChange in Mean Visual Function Questionnaire (VFQ-25)

The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.

Time frame:
Baseline, 12 months
Reported as:
Mean · Scores on a scale
Change in Mean Visual Function Questionnaire (VFQ-25)
Scores on a scaleRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Overall Composite8.1 ± 10.65.5 ± 11.39.1 ± 15.510.0 ± 15.9
General Health-1.4 ± 15.26.3 ± 18.61.7 ± 18.95.7 ± 20.3
General Vision15.0 ± 16.79.5 ± 16.320.0 ± 17.713.6 ± 23.4
Ocular Pain5.3 ± 15.75.3 ± 13.84.2 ± 20.83.4 ± 15.0
Near Activities13.3 ± 18.910.8 ± 20.612.3 ± 20.512.3 ± 23.2
Distance Activities8.9 ± 17.55.6 ± 15.37.8 ± 18.38.3 ± 23.4
Social Functioning3.4 ± 16.82.2 ± 12.03.3 ± 16.72.8 ± 21.1
Mental Health10.2 ± 14.92.9 ± 20.410.7 ± 21.715.1 ± 18.3
Role Difficulties4.8 ± 26.810.6 ± 20.514.6 ± 29.924.4 ± 27.8
Dependency3.2 ± 9.20.4 ± 16.65.1 ± 16.74.4 ± 12.8
Driving (BRVO n=44,31) (CRVO n=42,16)11.7 ± 23.94.8 ± 21.314.2 ± 24.617.7 ± 25.1
Color Vision(BRVO n=52,39)0.5 ± 10.51.9 ± 10.60.4 ± 17.5-1.1 ± 14.4
Peripheral Vision(BRVO n=51,40)10.3 ± 24.16.9 ± 23.311.7 ± 25.014.8 ± 22.7
SecondaryChange in SF-36 Summary Scores

The SF-36 measures the impact of disease on overall quality of life and consists of eight subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health. A positive change from Baseline score indicates improvement in quality of life.

Time frame:
Baseline, month 12
Reported as:
Mean · Score on a scale
Change in SF-36 Summary Scores
Score on a scaleRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Physical Component(BRVO n=50,39) (CRVO n=58,20)1.6 ± 5.00.2 ± 7.0-1.1 ± 8.21.3 ± 7.2
Mental Component (BRVO n=50,39) (CRVO n=58,20)3.3 ± 9.72.1 ± 13.22.1 ± 9.32.4 ± 12.4
SecondaryChange in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores

The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).

Time frame:
Baseline, month 12
Reported as:
Mean · Score on a scale
Change in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores
Score on a scaleRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Change in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores3.3 ± 15.22.6 ± 16.91.5 ± 16.40.2 ± 20.4
SecondaryTime to the First Retreatment of Both Treatment Arms

Time to the first retreatment

Time frame:
6 months
Reported as:
Median · Days
Time to the First Retreatment of Both Treatment Arms
DaysRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
Time to the First Retreatment of Both Treatment Arms37 (3 to 56)NA (328 to NA)62 (5 to 67)NA (309 to NA)

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab (BRVO)—2/52 (3.8%)35/52 (67.3%)
Dexamethasone (BRVO)—3/40 (7.5%)28/40 (70%)
Ranibizumab (CRVO)—6/61 (9.8%)45/61 (73.8%)
Dexamethasone (CRVO)—1/22 (4.5%)16/22 (72.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
RETINAL DETACHMENT (Study eye)Eye disorders0/520/400/611/22
VITREOUS HAEMORRHAGE (Study eye)Eye disorders0/520/401/611/22
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders1/521/400/610/22
ROTATOR CUFF SYNDROMEMusculoskeletal and connective tissue disorders0/521/400/610/22
LUMBAR RADICULOPATHYNervous system disorders0/521/400/610/22
PSORIASISSkin and subcutaneous tissue disorders0/521/400/610/22
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/520/400/610/22
GLAUCOMA (Fellow eye)Eye disorders0/520/401/610/22
GLAUCOMA (Study eye)Eye disorders0/520/401/610/22
IRIS NEOVASCULARISATION (Study eye)Eye disorders0/520/401/610/22
Most frequent other events
Showing 10 of 59
Most frequent other events
EventRanibizumab (BRVO)Dexamethasone (BRVO)Ranibizumab (CRVO)Dexamethasone (CRVO)
INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations3/5210/403/614/22
MACULAR OEDEMA (Study eye)Eye disorders9/523/4014/613/22
NASOPHARYNGITISInfections and infestations9/523/4012/613/22
EYE PAIN (Study eye)Eye disorders4/520/407/614/22
CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders2/527/403/613/22
OCULAR HYPERAEMIA (Study eye)Eye disorders7/523/404/613/22
VISUAL ACUITY REDUCED (Study eye)Eye disorders4/524/408/611/22
LACRIMATION INCREASED (Study eye)Eye disorders6/522/402/612/22
OCULAR DISCOMFORT (Study eye)Eye disorders2/524/401/610/22
RETINAL ISCHAEMIA (Study eye)Eye disorders5/524/402/610/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RanibizumabDexamethasoneTotal
Mean65.6 ± 9.963.3 ± 10.364.8 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabDexamethasoneTotal
Female642690
Male493685
08

Study locations

37 sites
  • Novartis Investigative Site
    Augsburg, 85155, Germany
  • Novartis Investigative Site
    Bad Rothenfelde, 49214, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Bremen, 28209, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Darmstadt, 64297, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Düsseldorf, 40212, Germany
  • Novartis Investigative Site
    Frankfurt, 60318, Germany
  • Novartis Investigative Site
    Freiburg i. Br, 79106, Germany
  • Novartis Investigative Site
    Glauchau, 08371, Germany
  • Novartis Investigative Site
    Göttingen, 37075, Germany
  • Novartis Investigative Site
    Halle, 06114, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Ingolstadt, 85049, Germany
  • Novartis Investigative Site
    Karlsruhe, 76133, Germany
  • Novartis Investigative Site
    Karlsruhe, 76199, Germany
  • Novartis Investigative Site
    Koeln, 50935, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Minden, 32427, Germany
  • Novartis Investigative Site
    Muelheim, 45468, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    München, 80336, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Recklinghausen, 45657, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
  • Novartis Investigative Site
    Sulzbach, 66280, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89075, Germany
  • Novartis Investigative Site
    Wolfsburg, 38442, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2012
First posted
Apr 18, 2012
Start
May 2012
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
May 17, 2016
Last update
May 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01580020
Responsible party
Sponsor
First posted
Apr 18, 2012
Start date
May 2012
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
May 17, 2016
Last update
May 17, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion